A PHASE II, ADAPTIVE TRIAL DESIGN EXAMINING THE PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF MODIFIED RELEASE AMPHETAMINE (HLD100, FORMULATIONS B, C AND E)) IN ADOLESCENTS AND CHILDREN WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD):